Eflornithine plus Gleostine improved OS and PFS in recurrent grade 3 IDH-mutated astrocytoma compared to Gleostine alone. The STELLAR study reclassified patients using updated WHO 2021 criteria, ...

Currently patients with glioblastoma have a median survival of approximately 14.6 months and 5-year survival rates below 5%.

Voranigo plus Temodar was safe in glioma with IDH1/2 mutations. Among patents with IDH1- or IDH2-mutant glioma, the treatment ...

Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive ...

Gomekli showed an 87% overall response rate in pediatric low-grade glioma with MAPK pathway activation, with a recommended ...

Early data indicate Voranigo (vorasidenib) is being rapidly adopted in patients with isocitrate dehydrogenase–mutated glioma, ...

Recent real-world study findings have identified a potential unmet need for an effective early treatment with minimal ...

The lidERA Breast Cancer study is a phase 3, randomized, open-label trial testing whether the adjuvant therapy giredestrant ...

Baker, a patient and patient advocate based in the United Kingdom, received a diagnosis of essential thrombocythemia (ET) in ...

Nona Baker received a diagnosis of essential thrombocythemia in 1991, followed by polycythemia vera in 2004. It’s been nearly ...

Immune-based therapies are transforming advanced liver cancer care, resulting in curative options previously considered ...

GISTs are solid tumors, primarily in the stomach, characterized by KIT and EGFR mutations, with Gleevec as a key treatment.